VANDA PHARMACEUTICALS INC.: 10-K filed 2012-03-09
What VANDA PHARMACEUTICALS INC. reported in its annual report filed 2012-03-09 (fiscal FY 2011): 36 published measures, 92 facts as tagged in accession 0001193125-12-105284.
This filing
- Form
- 10-K (annual report)
- Filed
- 2012-03-09
- Fiscal period
- fiscal FY 2011
- Accession
- 0001193125-12-105284 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All VANDA PHARMACEUTICALS INC. filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2011-12-31 | 182,618,000 | USD | |
| At 2010-12-31 | 213,101,000 | USD |
Total liabilities
Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2011-12-31 | 149,144,000 | USD | |
| At 2010-12-31 | 175,370,000 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2011-12-31 | 33,474,000 | USD | |
| At 2010-12-31 | 37,731,000 | USD | |
| At 2009-12-31 | 23,031,000 | USD | |
| At 2008-12-31 | 46,020,000 | USD |
Cash and cash equivalents
Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2011-12-31 | 87,923,000 | USD | |
| At 2010-12-31 | 42,559,000 | USD | |
| At 2009-12-31 | 205,295,000 | USD | |
| At 2008-12-31 | 39,079,000 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2011-01-01 to 2011-12-31 | -9,802,000 | USD | 365 |
| 2010-01-01 to 2010-12-31 | 7,192,000 | USD | 365 |
| 2009-01-01 to 2009-12-31 | -35,859,000 | USD | 365 |
Operating cash flow
Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2011-01-01 to 2011-12-31 | -28,410,000 | USD | 365 |
| 2010-01-01 to 2010-12-31 | -10,898,000 | USD | 365 |
| 2009-01-01 to 2009-12-31 | 169,336,000 | USD | 365 |
Capital expenditure payments
Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2011-01-01 to 2011-12-31 | 275,000 | USD | 365 |
Financing cash flow
Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2011-01-01 to 2011-12-31 | 25,000 | USD | 365 |
| 2010-01-01 to 2010-12-31 | 3,784,000 | USD | 365 |
| 2009-01-01 to 2009-12-31 | 1,619,000 | USD | 365 |
Investing cash flow
Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2011-01-01 to 2011-12-31 | 73,749,000 | USD | 365 |
| 2010-01-01 to 2010-12-31 | -155,622,000 | USD | 365 |
| 2009-01-01 to 2009-12-31 | -4,739,000 | USD | 365 |
Retained earnings or deficit
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2011-12-31 | -263,443,000 | USD | |
| At 2010-12-31 | -253,641,000 | USD |
Basic weighted-average shares
Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2011-01-01 to 2011-12-31 | 28,106,831 | shares | 365 |
| 2010-01-01 to 2010-12-31 | 27,916,388 | shares | 365 |
| 2009-01-01 to 2009-12-31 | 27,015,271 | shares | 365 |
Diluted weighted-average shares
Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2011-01-01 to 2011-12-31 | 28,106,831 | shares | 365 |
| 2010-01-01 to 2010-12-31 | 28,534,617 | shares | 365 |
| 2009-01-01 to 2009-12-31 | 27,015,271 | shares | 365 |
Basic earnings per share
Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2011-01-01 to 2011-12-31 | -0.35 | USD/shares | 365 |
| 2010-01-01 to 2010-12-31 | 0.26 | USD/shares | 365 |
| 2009-01-01 to 2009-12-31 | -1.33 | USD/shares | 365 |
Diluted earnings per share
Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2011-01-01 to 2011-12-31 | -0.35 | USD/shares | 365 |
| 2010-01-01 to 2010-12-31 | 0.25 | USD/shares | 365 |
| 2009-01-01 to 2009-12-31 | -1.33 | USD/shares | 365 |
Income tax expense or benefit
Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2011-01-01 to 2011-12-31 | -444,000 | USD | 365 |
| 2010-01-01 to 2010-12-31 | 2,077,000 | USD | 365 |
Net property, plant and equipment
Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2011-12-31 | 964,000 | USD | |
| At 2010-12-31 | 937,000 | USD |
Share-based compensation expense
Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2011-01-01 to 2011-12-31 | 5,501,000 | USD | 365 |
| 2010-01-01 to 2010-12-31 | 4,982,000 | USD | 365 |
| 2009-01-01 to 2009-12-31 | 11,230,000 | USD | 365 |
Operating income or loss
Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2011-01-01 to 2011-12-31 | -10,707,000 | USD | 365 |
| 2010-01-01 to 2010-12-31 | 8,838,000 | USD | 365 |
| 2009-01-01 to 2009-12-31 | -35,948,000 | USD | 365 |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2011-12-31 | 153,501,000 | USD | |
| At 2010-12-31 | 200,573,000 | USD |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2011-12-31 | 31,619,000 | USD | |
| At 2010-12-31 | 31,027,000 | USD |
Current accounts payable
Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2011-12-31 | 996,000 | USD | |
| At 2010-12-31 | 648,000 | USD |
Net finite-lived intangible assets
Finite-lived intangible assets after amortization. This excludes goodwill and should not be combined with indefinite-lived intangible assets without checking scope.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2011-12-31 | 8,027,000 | USD | |
| At 2010-12-31 | 9,522,000 | USD |
Net current accounts receivable
Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2011-12-31 | 1,618,000 | USD | |
| At 2010-12-31 | 511,000 | USD |
Research and development expense
Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2011-01-01 to 2011-12-31 | 28,996,000 | USD | 365 |
| 2010-01-01 to 2010-12-31 | 12,338,000 | USD | 365 |
| 2009-01-01 to 2009-12-31 | 13,874,000 | USD | 365 |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2011-12-31 | 28,117,026 | shares | |
| At 2010-12-31 | 28,041,379 | shares |
Accumulated other comprehensive income or loss
Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2011-12-31 | 21,000 | USD | |
| At 2010-12-31 | 2,000 | USD |
Other noncurrent assets
Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2011-12-31 | 84,000 | USD | |
| At 2010-12-31 | 0 | USD |
Accrued current liabilities
Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2011-12-31 | 3,381,000 | USD | |
| At 2010-12-31 | 1,324,000 | USD |
Comprehensive income or loss
Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2011-01-01 to 2011-12-31 | -9,783,000 | USD | 365 |
| 2010-01-01 to 2010-12-31 | 7,194,000 | USD | 365 |
| 2009-01-01 to 2009-12-31 | -35,838,000 | USD | 365 |
General and administrative expense
General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2011-01-01 to 2011-12-31 | 11,486,000 | USD | 365 |
| 2010-01-01 to 2010-12-31 | 10,147,000 | USD | 365 |
| 2009-01-01 to 2009-12-31 | 23,724,000 | USD | 365 |
Depreciation, depletion and amortization
Combined depreciation, depletion and amortization for the period. A noncash allocation of asset cost, not a measure of maintenance spending.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2011-01-01 to 2011-12-31 | 469,000 | USD | 365 |
| 2010-01-01 to 2010-12-31 | 336,000 | USD | 365 |
| 2009-01-01 to 2009-12-31 | 442,000 | USD | 365 |
Amortization of intangible assets
Amortization recognized on finite-lived intangible assets. It follows acquisition accounting and does not indicate the intangibles are losing usefulness at that rate.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2011-01-01 to 2011-12-31 | 1,495,000 | USD | 365 |
| 2010-01-01 to 2010-12-31 | 1,495,000 | USD | 365 |
| 2009-01-01 to 2009-12-31 | 983,000 | USD | 365 |
Deferred income tax expense or benefit
The deferred portion of income tax expense or benefit, arising from timing differences. It is not tax paid in the period.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2011-01-01 to 2011-12-31 | 1,821,000 | USD | 365 |
| 2010-01-01 to 2010-12-31 | -1,821,000 | USD | 365 |
Change in accounts receivable
The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2011-01-01 to 2011-12-31 | 1,107,000 | USD | 365 |
| 2010-01-01 to 2010-12-31 | -2,653,000 | USD | 365 |
| 2009-01-01 to 2009-12-31 | 3,164,000 | USD | 365 |
Change in inventories
The cash flow adjustment for the change in inventories during the period. A positive value under this concept means inventory grew and reduced operating cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2010-01-01 to 2010-12-31 | -2,399,000 | USD | 365 |
| 2009-01-01 to 2009-12-31 | 2,399,000 | USD | 365 |
Change in accounts payable
The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2011-01-01 to 2011-12-31 | 348,000 | USD | 365 |
| 2010-01-01 to 2010-12-31 | -1,776,000 | USD | 365 |
| 2009-01-01 to 2009-12-31 | 1,911,000 | USD | 365 |
Inspect the source
- Entity
- VANDA PHARMACEUTICALS INC. / CIK 0001347178
- Captured
- 2026-09-20T07:54:54.067Z
- SEC response SHA-256
73fc153c337a0fde6ea6f321d6378d9f94925087244e6f7cab0e2262e4e90436
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001347178.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))